Multimodality therapy of colorectal cancer;Multimodale Therapie des kolorektalen Karzinoms

Internist

Volumn 51, Issue 11, 2010, Pages 1366-1373

  Hacker, U ^a   Hallek, M ^a   Kubicka, S ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adjuvant therapy; Chemotherapy; Colorectal cancer; Liver metastases; Radiotherapy

Indexed keywords

FLUOROPYRIMIDINE; OXALIPLATIN; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; HUMAN; LIVER METASTASIS; MICROSATELLITE INSTABILITY; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLECTOMY; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE;

EID: 78650418399     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-010-2671-9     Document Type: Article

References (30)

1. Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644-657
2. Albert SR, Sargent DJ, Smyrk TC et al (2010) Adjuvant mFOLFOX with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28 (Suppl): 18s (abstr CRA3507)
3. André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116
4. André T, Sargent D, Tabernero J et al (2006) Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 13:887-898
5. Aschele C, Pinto C, Cordio S et al (2009) Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. J Clin Oncol 27 (Suppl): 18s (abstr CRA4008)
6. Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114-1123
7. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215-1223
8. Collette L, Bosset JF, den Dulk M et al (2007) Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 25:4379-4386
9. Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676
10. Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38-47
11. Gerard JP, Azria D, Gourgou-Bourgade S et al (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638-1644
12. Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620-4625
13. Haller D, Taberno J, Maroun J et al (2009) First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). Eur J Cancer Suppl 7:4
14. Heald RJ, Ryall RD (1986) Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1:1479-1482
15. Hofheinz R, Wenz F, Post S et al (2009) Capecitabine (Cape) vs. 5-fluorouracil (5-FU)-based (neo-) adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Safety results of a randomized, phase III trial. J Clin Oncol: 4014
16. Jackson McCleary NA, Meyerhardt J, Green E et al (2009) The ACCENT Collaborative Group. Impact of older age on the efficacy of newer adjuvant therapies in >12, 500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database. J Clin Oncol 27 (Suppl): 15s (abstr 4010)
17. Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638-646
18. Kuebler JP, Wieand HS, O'Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198-2204
19. Mitry E, Fields AL, Bleiberg H et al (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26:4906-4911
20. Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery vs. surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007-1016
21. O'Connell MJ (2009) Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. J Clin Oncol 27:3082-3084
22. Quasar Collaborative Group, Gray R, Barnwell J, McConkey C et al (2007) Adjuvant chemotherapy vs. observation in patients with colorectal cancer: a randomised study. Lancet 370:2020-2029
23. Rodel C, Arnold D, Hipp M et al (2008) Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 70:1081-1086
24. Rodel C, Liersch T, Hermann RM et al (2007) Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25:110-117
25. Sauer R, Becker H, Hohenberger W et al (2004) Preoperative vs. postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740
26. Schmiegel W, Pox C, Adler G et al (2004) S3-Guidelines conference "colorectal carcinoma" 2004. Z Gastroenterol 42:1129-1177
27. Schmiegel W, Reinacher-Schick A, Arnold D et al (2008) Update S3-guideline "colorectal cancer" 2008. Z Gastroenterol 46:799-840
28. Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696-2704
29. Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147
30. Wolmark N, Yothers G, O'Connell JM et al (2009) A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol 27 (Suppl): 18s (abstr LBA4)